Armata Pharmaceuticals, Inc. (ARMP)

[Seel]

To Investor Relations,
It would be very helpful to investors researching your company if anticipated trial initiation windows were included in pipeline descriptions on your website. Broad windows are acceptable to the average investor, ie, 'first half 2016' as evidenced by the information typically provided by many biotech companies on their pipeline page. There is no comprehensive description in pr's, corporate updates or on pipeline page about estimated timing of initiation of human trials. Instead, disparate references are made here and there throughout the years communications.
Organization in accessible area of prospective pipeline timeline goals, at least for phase one studies, would be much appreciated.
Thank you,